RxDoctor Payments Data

Usman Sheriff, MD

Cardiovascular Disease · Harlingen, TXNPI 1356396303

Payments from drug & device makers

$44,689in general payments, 2019–2025

Across 179 payments — averaging $249.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$35K
  • Surmodics, Inc.$2K
  • Bard Peripheral Vascular, Inc.$2K
  • Penumbra, Inc.$2K
  • Medtronic$716
  • Philips North America LLC$673
  • plus $3K from 17 others

What the payments were for

  • Travel & lodging$5,85213%
  • Food & beverage$4,0719%
  • Education$990%
  • Other$34,66778%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,689 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$575,364
Medicare patients
453
Services billed
3,716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban460$383,074
EntrestoSacubitril/Valsartan60$60,100
FarxigaDapagliflozin Propanediol56$53,240
XareltoRivaroxaban48$38,976
Repatha SyringeEvolocumab12$16,957
BrilintaTicagrelor20$15,246
ClopidogrelClopidogrel Bisulfate641$4,068
Carvedilol526$3,296
Metoprolol Succinate294$3,024
Midodrine Hcl27$2,846
Metoprolol Tartrate514$2,832
Losartan Potassium349$2,464
Ezetimibe92$2,256
Rosuvastatin Calcium225$2,203
Amiodarone Hcl113$1,924

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$420$383,074460 claims
AstraZenecaFarxiga, Brilinta$165$68,48676 claims
NovartisEntresto$124$60,10060 claims
Johnson & JohnsonXarelto$86$38,97648 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Harlingen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →